Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

Nature Biotechnology

Volumn 24, Issue 8, 2006, Pages 1005-1015

  McNamara II, James O ^a   Andrechek, Eran R ^b   Wang, Yong ^a   Viles, Kristi D ^a   Rempel, Rachel E ^b   Gilboa, Eli ^a   Sullenger, Bruce A ^a   Giangrande, Paloma H ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; GENES; MATHEMATICAL MODELS; PROTEINS; TUMORS;

CHIMERAS; SIRNA TARGET PROTEINS; SMALL INTERFERING RNAS (SIRNA); XENOGRAFT MODELS;

RNA;

APTAMER; CELL SURFACE RECEPTOR; REAGENT; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER THERAPY; CELL DEATH; CELL SPECIFICITY; CELL TYPE; CHIMERA; CONTROLLED STUDY; DRUG BINDING; DRUG COST; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; TUMOR GROWTH; TUMOR REGRESSION; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; GENE SILENCING; GENE TARGETING; GENE TRANSFER TECHNIQUES; HUMANS; RNA, SMALL INTERFERING;

EID: 33747031960     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1223     Document Type: Article

References (37)

1. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
2. Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
3. Yano, J. et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10, 7721-7726 (2004).
4. Fountaine, T.M., Wood, M.J. & Wade-Martins, R. Delivering RNA interference to the mammalian brain. Curr. Gene Ther. 5, 399-410 (2005).
5. Devroe, E. & Silver, P.A. Therapeutic potential of retroviral RNAi vectors. Expert Opin. Biol. Ther. 4, 319-327 (2004).
6. Anderson, J., Banerjea, A., Planelles, V. & Akkina, R. Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res. Hum. Retroviruses 19, 699-706 (2003).
7. Lewis, D.L. & Wolff, J.A. Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods Enzymol. 392, 336-350 (2005).
8. Schiffelers, R.M. et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149 (2004).
9. Urban-Klein, B. et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12, 461-466 (2005).
10. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
11. Lorenz, C. et al. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14, 4975-4977 (2004).
12. Minakuchi, Y. et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32, e109 (2004).
13. Takeshita, F. et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA 102, 12177-12182 (2005).
14. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005).
15. Hu-lieskovan, S., Heidel, J.D., Bartlett, D.W., Davis, M.E. & Triche, T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, noviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992 (2005).
16. Lupold, S.E., Hicke, B.J., Lin, Y. & Coffey, D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029-4033 (2002).
17. Reagan-Shaw, S. & Ahmad, N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J. 19, 611-613 (2005).
18. Takai, N. et al. Polo-like kinases (Plks) and cancer. Oncogene 24, 287-291 (2005).
19. Eckerdt, F., Yuan, J. & Strebhardt, K. Polo-like kinases and oncogenesis. Oncogene 24, 267-276 (2005).
20. Cory, S. & Adams, J.M. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8, 5-6 (2005).
21. Pestourie, C., Tavitian, B. & Duconge, F. Aptamers against extracellular targets for in vivo applications. Biochimie 87, 921-930 (2005).
22. Nimjee, S.M., Rusconi, C.P. & Sullenger, B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555-583 (2005).
23. Israeli, R.S. et al. Expression of the prostate-specific membrane antigen. Cancer Res. 54, 1807-1811 (1994).
24. Doi, N. et al. Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiation factors. Curr. Biol. 13, 41-46 (2003).
25. Murchison, E.P., Partridge, J.F., Tam, O.H., Cheloufi, S. & Hannon, G.J. Characterization of Dicer-deficient murine embryonic stem cells. Proc. Natl. Acad. Sci. USA 102, 12135-12140 (2005).
26. Kim, D.H. et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222-226 (2005).
27. Sledz, C.A. et al. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839 (2003).
28. Kariko, K., Bhuyan, P., Capodici, J. & Weissman, D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172, 6545-6549 (2004).
29. Allerson, C.R. et al. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48, 901-904 (2005).
30. Layzer, J.M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-771 (2004).
31. Cui, Y., Ulrich, H. & Hess, G.P. Selection of 2′-fluoro- modified RNA aptamers for alleviation of cocaine and MK-801 inhibition of the nicotinic acetylcholine receptor. J. Membr. Biol. 202, 137-149 (2004).
32. Park, K.W. Protamine and protamine reactions. Int. Anesthesiol. Clin. 42, 135-145 (2004).
33. Shepherd, G.M. Hypersensitivity reactions to drugs: evaluation and management. Mt. Sinai J. Med. 70, 113-125 (2003).
34. Padilla, R. & Sousa, R. Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2′-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res. 27, 1561-1563 (1999).
35. Myers, J.W., Jones, J.T., Meyer, T. & Ferrell, J.E., Jr. Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing. Nat. Biotechnol. 21, 324-328 (2003).
36. Wang, Y., Wang, H., Li, C.Y. & Yuan, F. Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery. Mol. Cancer Ther. 5, 362-366 (2006).
37. McGuire, S. & Yuan, F. Quantitative analysis of intratumoral infusion of color molecules. Am. J. Physiol. Heart Circ. Physiol. 281, H715-H721 (2001).